Proteinuria in Glomerulonephritis: Myfortic® (GloMY)
| ISRCTN | ISRCTN11937028 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN11937028 |
| EudraCT/CTIS number | 2009-016003-26 |
| Secondary identifying numbers | V2, EuDRACT No: 2009-016003-26 |
- Submission date
- 19/04/2010
- Registration date
- 27/05/2010
- Last edited
- 21/11/2016
- Recruitment status
- Stopped
- Overall study status
- Stopped
- Condition category
- Urological and Genital Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English Summary
Not provided at time of registration
Contact information
Mrs Elizabeth Brettell
Scientific
Scientific
Birmingham Clinical Trials Unit
School of Cancer Sciences
College of Medical and Dental Sciences
Robert Aitken Institute
University of Birmingham
Edgbaston
Birmingham
B15 2TT
United Kingdom
Study information
| Study design | National multicentre randomised controlled open label pilot trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Will be available at: http://www.bctu.bham.ac.uk/glomy |
| Scientific title | Randomised pilot trial of Myfortic® for the treatment of primary proteinuric glomerulonephritis |
| Study acronym | GloMY |
| Study hypothesis | To determine the feasibility of running a full-scale phase III randomised trial of Myfortic ®plus short course steroids versus standard care in patients with Focal Segmental Glomerulosclerosis (FSGS) or Immunoglobulin A Nephropathy (IgAN). The trial will also provide preliminary comparative data on the efficacy of Myfortic® plus short course steroids in inducing sustained response (partial or complete) in a well-defined cohort of patients with primary proteinuric glomerulonephritis (FSGS and IgAN) that will inform the sample size required to design a large prospective randomised study investigating the effect of Myfortic®. |
| Ethics approval(s) | West of Scotland Ethics Committee 1, 04/05/2010, ref: 10/S0703/27 |
| Condition | Renal; primary proteinuric glomerulonephritis |
| Intervention | Intervention group for both FSGS and IgAN patients (Myfortic® and short course of steroids): Myfortic® 720mg b.d. continued for 2 years, along with prednisolone, starting at dose of 1mg/kg (up to a maximum of 60mg) tapered to 0mg by 10 weeks. Standard care for FSGS patients (High-dose steroids - prednisolone): Prednisolone, starting at dose of 1mg/kg (up to a maximum of 60mg) until complete remission or a maximum of 6 months treatment. If complete remission is achieved, prednisolone will be tapered to 0mg over the following 10 weeks. In those achieving partial remission, prednisolone will be continued for a further month, and then tapered to 5mg over 8 weeks, and then maintained at 5mg until 2 years. Standard care for IgAN patients: No treatment. All patients receive 2yrs treatment and are followed up until the end of the trial which is at 4yrs. So all patients will be followed up for at least two years after date of randomisation. So for patients who enter at the trial start they will have 2yrs treatment and a further 2 yrs follow-up, and patients entering at the end of the 2yr recruitment period will just have 2rys of treatment and follow-up. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase III |
| Drug / device / biological / vaccine name(s) | Mycophenolic acid (Myfortic®), prednisolone |
| Primary outcome measure | Proportion of patients achieving complete or partial remission by 24 weeks sustained (relapse free) for 12 months. |
| Secondary outcome measures | 1. Proportion achieving partial remission 2. Time to partial remission 3. Proportion achieving complete remission 4. Time to complete remission 5. Time to relapse 6. Proportion of patients requiring alternative cytotoxic agent or treatment failure and renal function (estimated Glomerular Filtration Rate, proteinuria) 7. Treatment safety: 7.1. Cumulative dose of corticosteroids 7.2. Number of patients developing steroid induced diabetes 7.3. Number of patients having serious infections 7.4. Adverse events 7.5. Markers of bone turnover 7.5.1. procollagen type 1 aminoterminal propeptide (P1NP, a marker of bone formation) 7.5.2. β-C-terminal telopeptides of type 1 collagen (β-CTx, a marker of bone resorption) Data will be collected at baseline, at weeks 2 and 4, and then every 4 weeks out to 6 months post-randomisation, and then every 12 weeks for at least 2 years. This study will also enable the study forms to be piloted. |
| Overall study start date | 01/06/2010 |
| Overall study end date | 02/10/2012 |
| Reason abandoned (if study stopped) | Participant recruitment issue |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | 100 |
| Participant inclusion criteria | 1. Patients with new onset biopsy proven (within last year) primary FSGS with albumin <30g/dl OR patients with primary IgAN with biopsy findings E1 and T<2 using the Oxford classification and a minimum of 8 glomeruli in the biopsy 2. Proteinuria (Protein Creatinine Ratio, PCR>150) following at least 4 weeks treatment with maximal blood pressure lowering therapy (to include angiotensin blockade) to target blood pressure <125/75 mmHg 3. If female and of childbearing potential, must not be pregnant or breastfeeding, and agree to avoid pregnancy during and for 6 weeks following the last dose of study treatment 4. If male with a partner of childbearing potential, must agree to use adequate, medically approved, contraceptive precautions during and for 6 weeks following the last dose of study treatment. |
| Participant exclusion criteria | 1. Age <18 years 2. Secondary causes of FSGS 3. Secondary IgAN 4. Deteriorating renal function >20μmol/l each week for 3 weeks or more 5. Estimated Glomerular Filtration Rate (eGFR) <20 ml/min (using modification of diet in renal disease [MDRD] equation) 6. Poor blood pressure control (e.g. blood pressure ≥140/80 mmHg) 7. Previous treatment with immunosuppression therapies 8. Unable to receive immunosuppression treatments due to malignancy or active infection 9. Patients with systemic infection unless specific anti-infective therapy is employed 10. Diabetes 11. Known to have hepatitis B or C 12. Known to be HIV positive 13. Inability to give informed consent |
| Recruitment start date | 21/10/2010 |
| Recruitment end date | 12/08/2012 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Birmingham Clinical Trials Unit
Birmingham
B15 2TT
United Kingdom
B15 2TT
United Kingdom
Sponsor information
University Hospitals Birmingham NHS Foundation Trust (UK)
Not defined
Not defined
Dr. Chris Counsell
Research & Development Manager
Research & Development Office
HSRC Building
College of Medical and Dental Sciences
West Campus
University of Birmingham
Edgbaston
Birmingham
B15 2TT
United Kingdom
| Website | http://www.uhb.nhs.uk/research |
|---|---|
"ROR" |
https://ror.org/014ja3n03 |
Funders
Funder type
Industry
Novartis (UK) - Educational Grant (ref: ERL080AGB09T)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not expected to be made available |
| Publication and dissemination plan | As the study showed that it was not feasible to run a full-scale phase III randomised trial of Myfortic plus short course steroids versus standard care in patients with FSGS or IgAN, and we obtained very limited data to assess the preliminary comparative efficacy of Myfortic plus short course steroids in inducing sustained response in patients with FSGS or IgAN, there are no plans for publication. The study outcome has been disseminated to all collaborators and the GloMY collaborators will all be sent a summary of this report. All participants were informed of the outcome and end of trial via a Research Ethics Committee approved letter via their clinician. |
| IPD sharing plan | The datasets generated during and/or analysed during the current study is not expected to be made available. As the study showed that it was not feasible to run a full-scale phase III randomised trial of Myfortic plus short course steroids versus standard care in patients with FSGS or IgAN, and we obtained very limited data to assess the preliminary comparative efficacy of Myfortic plus short course steroids in inducing sustained response in patients with FSGS or IgAN, there are no plans for publication. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| HRA research summary | 28/06/2023 | No | No |
Editorial Notes
21/11/2016: Only 12 patients were recruited to this study. This was despite recruitment being open for 2 years, 26 sites participating and several protocol amendments to facilitate recruitment. At this rate of patient entry, the recruitment phase of the study would have needed to continue for a further 7-10 years. The primary aim of the study was to assess the feasibility of conducting an interventional trial in primary glomerulonephritis within the UK rather than to assess efficacy of Myfortic in the treatment of these diseases. Given this aim, the TSC did not think it was feasible to continue recruitment for such a prolonged period of time, hence the decision to close the trial. The study therefore showed that it was not feasible to run a full-scale phase III randomised trial of Myfortic plus short course steroids versus standard care in patients with FSGS or IgAN.
The overall trial end date has been updated from 01/06/2014 to 02/10/2012 and the recruitment dates from 01/06/2010 - 01/06/2014 to 21/10/2010 - 21/08/2012.
18/11/2016: No publications found in PubMed, verifying study status with principal investigator.
